Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 2 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Line item | Helios Pharma | Weekend | New Medi | Medi-Hels | Deilait Kompani |
|---|---|---|---|---|---|
| Total Revenue | 645 | 345 | — | — | — |
| Total COGS | -149 | -183 | — | — | — |
| Gross Profit | 496 | 162 | — | — | — |
| Gross Margin | 76.8% | 47.0% | — | — | — |
| Total Operating Expenses | -654 | -127 | — | — | — |
| EBITDA | -158 | 35 | — | — | — |
| EBITDA Margin | -24.5% | 10.1% | — | — | — |
| Total D&A | -3 | 0 | — | — | — |
| EBIT / Operating Income | -161 | 35 | — | — | — |
| Total Interest Income | 411 | — | — | — | — |
| Total Other Income | -178 | — | — | — | — |
| Profit Before Tax | 72 | 35 | — | — | — |
| Total Income Tax | 0 | 0 | — | — | — |
| Net Profit / (Loss) | 72 | 35 | — | — | — |
| Net Margin | 11.1% | 10.1% | — | — | — |
Not every picked company reports every selected year — FY2024: 3 of 5 companies have no filing. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Weekend | Pharma | 10.1% | 37th pct | 110 |
| Helios Pharma | Pharma | -24.5% | 2nd pct | 110 |
| New Medi | Pharma | — | no FY data | 110 |
| Medi-Hels | Pharma | — | no FY data | 110 |
| Deilait Kompani | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.